Geoff von Maltzahn, Tessera Therapeutics CEO

Flag­ship-found­ed Tessera fu­els up with $300M 'to go on a re­al­ly big ad­ven­ture' in gene edit­ing

A few years ago, the gene edit­ing ap­proach at Tessera was just a “twin­kle in our eye,” CEO and co-founder Ge­off von Maltzahn said.

Nu­cle­as­es — the cru­cial ma­chin­ery un­der­ly­ing the gene edit­ing field — do a pret­ty good job of cut­ting DNA, al­low­ing sci­en­tists to switch off a spe­cif­ic gene. But von Maltzahn and Ja­cob Rubens, Tessera’s co-founder and chief in­no­va­tion of­fi­cer, saw the op­por­tu­ni­ty in be­ing able to do more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.